Abstract 8662: Advanced Heart Failure Care Status and Outcomes in Patients Undergoing Mitral Transcatheter Edge-to-Edge Repair
Abstract
Background: Mitral transcatheter valve edge-to-edge repair (M-TEER) has become a treatment option for heart failure (HF) patients with mitral regurgitation (MR) at high surgical risk. However, limited data exist for the association between hospitalization at a center providing advanced HF therapy and clinical outcomes in patients after M-TEER. Research Question: Is treatment at an advanced HF care center associated with improved clinical outcomes among HF patients undergoing M-TEER? Methods: We conducted a retrospective analysis of patients undergoing M-TEER between April 2018 and December 2021 using the J-MITRA Registry data. The primary outcome was major cardiovascular adverse events during a 2-year follow-up period after the procedure. The association between advanced HF care status (hospitals performing heart transplantation and/or VAD implantation) and the outcomes was evaluated with a mixed-effects Cox model. Results: Among 4,351 patients, 986 (23%) patients were treated at advanced HF care centers. The use of HF medications increased across fiscal years at both advanced HF centers and non-advanced centers. Cumulative incidence of primary outcome developed 9.26 per 100 person-years in the advanced HF centers and 10.57 per 100 person-years in the non-advanced HF centers. The Advanced HF status was associated with a lower risk of the primary outcome than the non-advanced HF status after adjustment (hazard ratio 0.72; 95% confidence interval, 0.54-0.96). In subgroup analyses, the association was consistent across age, sex, New York Heart Association class, left ventricular ejection fraction, MR etiology, and case volume strata. Conclusion: Advanced HF care status was associated with better outcomes among HF patients after M-TEER. Our findings suggest that multidisciplinary heart team management performed at advanced HF centers may be important for patients undergoing M-TEER.